FindTrial
Sign In

Study to understand clinical utility of Nebivolol and Telmisartan combination in Indian patients with Hypertension.

Drug utilization pattern and tolerability of Nebivolol-Telmisartan combination in Indian Hypertensive Patients: A retrospective cross-sectional study (INTEL-HT) - INTEL-HT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093314
Enrollment
15000
Registered
2025-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension Health Condition 2: I15- Secondary hypertension Health Condition 3: I11- Hypertensive heart disease

Interventions

Intervention1: Nil: Nil

Sponsors

Torrent Pharmaceuticals Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female patients aged more than or equal to 18 years 2. Patients diagnosed with hypertension and treated with FDC of nebivolol and telmisartan

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
1. Proportion of patients with hypertension on FDC of Nebivolol and telmisartan who also have diabetesTimepoint: Baseline—

Secondary

MeasureTime frame
1. Proportion of newly diagnosed patients with hypertension on FDC of Nebivolol & telmisartan who also have diabetes 2. Proportion of patients on fixed dose combination of nebivolol & telmisartan experiencing adverse eventsTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Mukesh Gabhane

Torrent Pharmaceuticals Ltd.

mukeshgabhane@torrentpharma.com07069000639

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026